Sulpiride, an oral selective antagonist of the dopamine D 2 receptor, is widely used for the treatment of schizophrenia, depression, and gastric and duodenal ulcers. 6, 7) After oral administration of 100-400 mg in humans, peak plasma levels of 0.2-1.5 mg/ml are obtained within 1-3 h, and the elimination half life is 7-8 h. [8] [9] [10] After intravenous administration of sulpiride, 70% of the dose is recovered as unchanged drug in urine, as compared to 15% after oral administration, 11) and the bioavailability of the oral form is 25-36%. 10, 11) After oral dosing of 14 C-labeled sulpiride, urinary excretion of radioactivity was 27-52%, and more than 95% of the radioactivity recovered in the urine and feces is unchanged sulpiride. 8) It has been reported that sulpiride is coadministered with other drugs including olanzapine, 12, 13) fluvoxamine, 14) and cimetidine 15) for the treatment of schizophrenia, depression, and gastro-duodenal ulcers, respectively. However, there are few studies on the effect of sulpiride on human hepatic CYP-mediated drug-metabolizing activity, nor have there been any in vivo pharmacokinetic interaction studies.
Recent studies have shown that inhibition constants (K i ) for drugs as inhibitors of microsomal drug-metabolizing enzymes, such as CYP, should be correlated in conjunction with the extent of nonspecific binding to components of the in vitro matrix by measurement of the unbound fraction under the incubation condition to yield more accurate determination of the constant. [16] [17] [18] In the present study, we investigated the effects of sulpiride on specific activities by CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 in human liver microsomes, and the results suggest that sulpiride is not an inhibitor of these CYPs.
MATERIALS AND METHODS

Materials
Pooled human liver microsomes from 46 individuals were obtained from XenoTech (Lenexa, KS, U.S.A.). Sulpiride, 7-ethoxyresorufin, resorufin, tolbutamide, debrisoquine sulfate, chlorzoxazone, nifedipine, sulfaphenazole, tranylcypromine, quinidine hydrochloride, and diethyldicarbamate were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). S-Mephenytoin, 4Ј-hydroxymephenytoin, hydroxytolbutamide, 6-hydroxychlorzoxazone, oxidized nifedipine, and 6b-hydroxytestosterone were obtained from Ultrafine Chemicals (Manchester, U.K.). Testosterone, phenobarbital sodium, and p-hydroxybenzoic acid isopropyl were purchased from Nacalai Tesque (Kyoto, Japan), Wako Pure Chemicals (Osaka, Japan), and Tokyo Chemical Industry (Tokyo, Japan), respectively. All other reagents were of the highest purity commercially available.
Determination of Human CYP Activities 7-Ethoxyresorufin O-deethylase activity (CYP1A2), debrisoquine 4-hydroxylase activity (CYP2D6), and nifedipine oxidase activity (CYP3A4) in the presence or absence of sulpiride were determined as described previously. 19) The incubation mixture consisted of 0.05-0.5 mg/ml of human microsomes, 2 mM NADP ϩ , 10 mM glucose-6-phosphate, 5 mM magnesium chloride, 1 unit/ml of glucose-6-phosphate dehydrogenase, 100 mM phosphate buffer (pH 7.4), and 5 ml of methanol or 5-50 mM sulpiride dissolved in methanol in a final volume of 500 ml.
19) The microsomal protein concentration in the mixture was 0.05 (nifedipine oxidation), 0.1 (for 7-ethoxyresorufin O-deethylation and testosterone 6b-hydroxylation), 0.2 (for chlorzoxazone 6-hydroxylation), or 0.5 mg/ml (for tolbutamide hydroxylation, S-mephenytoin 4Ј-hydroxylation, and debrisoquine 4-hydroxylation). Because the K m for 7-ethoxyresorufin O-deethylation, tolbutamide hydroxylation, S-mephenytoin 4Ј-hydroxylation, debrisoquine 4-hydroxylation, chlorzoxazone 6-hydroxylation, nifedipine oxidation, and testosterone 6b-hydroxylation by human liver microsomes were 0. 22 resorufin, tolbutamide, S-mephenytoin, debrisoquine, chlorzoxazone, nifedipine, and testosterone were 0.25, 200, 30, 100, 50, 10, and 50 mM, respectively, which are around the expected K m . Incubation was carried out at 37°C for 5 min (for testosterone 6b-hydroxylation), 10 min (for 7-ethoxyresorufin O-deethylation, chlorzoxazone 6-hydroxylation, and nifedipine oxidation), 30 min (for tolbutamide hydroxylation and S-mephenytoin 4Ј-hydroxylation), or 60 min (for debrisoquine 4-hydroxylation).
For the assay of hydroxytolbutamide, the reaction was terminated by the addition of 100 ml of 1 M hydrochloric acid. After 50 ml of 20 mg/ml phenobarbital sodium, an internal standard and 3 ml of ethyl acetate/hexane (1 : 1) was added, then the mixture was shaken for 10 min and centrifuged at 1900 g for 5 min. The organic phase (2.5 ml) was evaporated under nitrogen. The residue was dissolved immediately in 200 ml HPLC mobile phase (Eluent A) and 80 ml was injected onto an HPLC column. The HPLC system consisted of a Waters model 600S System Controller, Waters model 717 Autosampler, Waters model 486 Tunable Absorbance Detector, and an analytical column Inertsil ODS-3 (150ϫ4.6 mm I.D., GL Sciences Inc., Tokyo, Japan) equipped with a TSKguardgel ODS-80Ts cartridge (3.2ϫ 15 mm, Tosoh Co., Tokyo, Japan). The column temperature was set at 40°C, and a UV-detector was set at 240 nm. The mobile phase was 5 mM potassium dihydrogen phosphate/methanol (58 : 42) as eluent A and 5 mM potassium dihydrogen phosphate/methanol (20 : 80) as eluent B. Gradient conditions were 0-12 min, 0% B; 12-12.1 min, 0-100% B (linear gradient); 12.1-20 min, 100% B; 20-20.1 min, 100-0% B (linear gradient); 20.1-28 min 0% B. Flow rate was held at 1 ml/min for 12 min and increased to 1.4 ml/min at 12.1 min. Calibration curves were linear for hydroxytolbutamide concentrations from 0.2 to 10 mM.
For the assay of 4Ј-hydroxymephenytoin, the reaction was terminated by the addition of 100 ml of 1 M hydrochloric acid. After 100 ml of 2 mg/ml phenobarbital sodium, an internal standard, and 3 ml of ethyl acetate/hexane (1 : 1) was added, the mixture was shaken for 10 min and centrifuged at 1900 g for 5 min. The organic phase (2.5 ml) was evaporated under nitrogen. The residue was dissolved immediately in 200 ml HPLC mobile phase (Eluent A), and 80 ml was injected onto an HPLC column. The same HPLC system and column as described above were used, except that the UV-detector was set at 204 nm. The column temperature was set at 45°C. For the assay of 6-hydroxychlorzoxazone, the reaction was terminated by the addition of 25 ml of 85% phosphoric acid. After 50 ml of 20 mg/ml phenobarbital sodium, an internal standard, and 3 ml of ethyl acetate/hexane (1 : 1) was added, the mixture was shaken for 10 min and centrifuged at 1900 g for 5 min. The organic phase (2.5 ml) was evaporated under nitrogen. The residue was dissolved immediately in 200 ml HPLC mobile phase (Eluent A), and 80 ml was injected onto an HPLC column. The same HPLC system and column as described above were used except that the UV-detector was set at 240 nm. The column temperature was set at 40°C. The mobile phase was 20 mM sodium perchlorate buffer (pH 2.5)/methanol (68 : 32) as eluent A and 20 mM sodium perchlorate buffer (pH 2.5)/methanol (20 : 80) as eluent B. Gradient conditions were 0-18 min, 0% B; 18-18.1 min, 0-100% B (linear gradient); 18.1-25 min, 100% B; 25-25.1 min, 100-0% B (linear gradient); 25.1-35 min 0% B. Flow rate was held at 1 ml/min for 10 min and increased to 1.4 ml/min at 10.1 min. Calibration curves were linear for 4Ј-hydroxymephenytoin concentrations from 0.2 to 5 mM.
For the assay of 6b-hydroxytestosterone, the reaction was terminated by the addition of 3.5 ml of ethyl acetate, and the mixture was shaken for 10 min and centrifuged at 1900 g for 5 min. The organic phase (3 ml) was evaporated under nitrogen. The residue was dissolved immediately in 200 ml of 50% methanol, and 80 ml was injected onto an HPLC column. The same HPLC system as described above was used, except that the UV-detector was set at 239 nm. An analytical column was Inertsil ODS-2 (250ϫ4.6 mm I.D., GL Sciences Inc.) equipped with a TSKguardgel ODS-80Ts cartridge (3.2ϫ15 mm), and the column temperature was set at 50°C. For the positive control, 5 ml of 2 mM furafylline dissolved in methanol (CYP1A2), [20] [21] [22] 2 mM sulfaphenazole in 50% acetone (CYP2C9), [21] [22] [23] [24] 2.5 mM tranylcypromine in 50% acetone (CYP2C19), 22) 100 mM quinidine hydrochloride in water (CYP2D6), 21, 22, 25) or 50 mM ketoconazole in methanol (CYP3A4), 21, 23) or 50 ml of 1 mM diethyldithiocarbamate in water (CYP2E1) 21, 22) was added instead of sulpiride.
Determination of Free Fraction in Incubation Mixture
The incubation mixture consisted of human microsomes (0.05-0.5 mg/ml), 50 or 500 mM sulpiride, and 100 mM phosphate buffer (pH 7.4) in a final volume of 500 ml. After a 5-min incubation at 37°C, the mixture was centrifuged at 105000 g for 60 min at 25°C, 17, 18, 26) and the concentration of sulpiride in the supernatant was measured by HPLC with an analytical column, Inertsil ODS-3 (150ϫ4.6 mm I.D.). The column temperature was set at 40°C. The elution was conducted with 10% acetonitrile in 20 mM potassium phosphate buffer (pH 3.5) containing 0.1% triethylamine at a flow rate of 1 ml/min, and detection was by UV absorbance at 288 nm. Calibration curves were linear for sulpiride concentrations from 10 to 1000 mM.
RESULTS AND DISCUSSION
The inhibitory effects of sulpiride on metabolic activities in human hepatic microsomes are summarized in Table 1 . 7-Ethoxyresorufin O-deethylase, tolbutamide hydroxylase, Smephenytoin 4Ј-hydroxylase, debrisoquine 4-hydroxylase, chlorzoxazone 6-hydroxylase, nifedipine oxidase, and testosterone 6b-hydroxylase activities in the presence of sulpiride at a concentration of 50 or 500 mM were 86.0-107.3% of the control, indicating that sulpiride had neither inhibitory nor stimulatory effects. On the other hand, the enzyme activities decreased to less than 34.6% of the respective control activities by inhibitors of the positive control.
The free fractions of sulpiride in the incubation mixture (0.05-0.5 mg protein/ml) were determined at concentrations of 50 and 500 mM. The free fractions of sulpiride estimated by ultracentrifugation were more than 90.5%, and the values were constant through the protein concentrations (Table 2) . These results indicate that the protein binding of sulpiride in the incubation mixture is of minor importance.
When the substrate concentration is much lower than the K m value, the degree of inhibition (R) can be expressed by the following equation, independent of the inhibition type, except in the case of uncompetitive inhibition 27, 28) :
where I u is the unbound concentration of the inhibitor. Additionally, when the absorption rate is maximum, the maximum inflow concentration of the inhibitor into liver (I in,max ) can be expressed as:
where I p,max , R B , k a , D, Q H , and F a represent the maximum plasma concentration of the inhibitor in the circulation, blood-to-plasma concentration ratio, absorption rate constant, dose, hepatic blood flow, and the fraction absorbed from the gastrointestinal tract into the portal vein, respectively. After an oral dosing of 400 mg sulpiride in healthy volunteers, the peak plasma concentration (I p,max ) was 1.468 mg/ml (4.3 mM). 10) Protein binding of sulpiride in human plasma, which is measured by equilibrium dialysis, is 11-18% (mean; 14%). 29) Free fraction of I in,max for sulpiride after an oral dosing of 400 mg is calculated, using free fraction in plasma (f u )ϭ0.86, R B ϭ1 (R B was assumed to be 1 because R B has not been reported), k a ϭ0.1 min
Ϫ1
, Q H ϭ1610 ml/min, F a ϭ1 to avoid false-negative predictions, to be 66 mM. In this paper, we have demonstrated that the inhibition of human CYPs by sulpiride was not observed at 500 mM concentration (Table 1) , which is 8-fold higher than the predicted free fractions of I in,max . Therefore, it is speculated that the K i values would be much higher than the predicted free fractions of I in,max , even if sulpiride inhibited human CYPs, and the results suggest that sulpiride might not affect the pharmacokinetics or metabolism of drugs metabolized by CYPs. Additionally, there are no clinical reports that sulpiride increases the blood concentrations of other CYPmetabolized drugs as a result of its inhibition of metabolism.
In conclusion, the present study demonstrated that sulpiride at 500 mM concentration, which is 8-fold higher than the predicted free fractions of I in,max , did not inhibit human CYPs at all, suggesting that sulpiride would not cause clinically significant interactions with other drugs, which are metabolized by CYPs, via the inhibition of metabolism. 
